FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294163067> ?p ?o ?g. }

• W4294163067 endingPage "PO012" @default.
• W4294163067 startingPage "PO012" @default.
• W4294163067 abstract "Abstract Resistance to conventional chemotherapy remains a huge challenge in the clinical management and treatment of hepatoblastoma, the most common liver tumor of childhood. The in silico repurposing of drugs with known pharmacokinetics and safety profiles, which have been approved for other indications, represents a promising strategy to identify new drugs effective in chemoresistant hepatoblastoma. In this study, we integrated RNA sequencing-derived gene expression data into the pharmacologic perturbation prediction tool Connectivity Map (CMap) and identified the clinical widely used anthelmintic drug mebendazole as a putative drug to circumvent chemoresistance in hepatoblastoma. Consequently, we experimentally validated the efficacy of mebendazole in permanent and patient-derived xenograft cell lines that are resistant to cisplatin, the therapeutic backbone of hepatoblastoma treatment. Viability assays clearly indicated a potent reduction of tumor cell growth upon mebendazole treatment in a dose-dependent manner. In contrast, similar mebendazole concentrations had little inhibitory effect on the growth of normal neonatal and adult skin fibroblasts. The combination of mebendazole and cisplatin revealed a strong synergistic effect, which was comparable to the one seen with cisplatin and doxorubicin (cardiotoxic), the current standard treatment for high-risk hepatoblastoma patients. Moreover, mebendazole treatment resulted in reduced colony formation capability, induction of apoptosis, and cell cycle arrest of hepatoblastoma cells. Immunofluorescent staining of alpha-tubulin showed that mebendazole causes blockage of microtubule formation and subsequent RNA sequencing analyses confirmed the transcriptional downregulation of tubulins as the major mode of action of mebendazole treatment. Most importantly, mebendazole significantly reduced tumor growth in a subcutaneous xenograft transplantation mouse model. In conclusion, our results strongly support the clinical use of mebendazole as a replacement for doxorubicin in the treatment of chemoresistant hepatoblastoma. This could potentially not only improve outcome but also reduce severe long-term side effects. Citation Format: Qian Li, Salih Demir, Xuanwen Bao, Alexandra Wagner, Yanxin Fan, Stefano Cairo, Roland Kappler. In silico drug repurposing identifies mebendazole as a treatment option for chemoresistant hepatoblastoma [abstract]. In: Proceedings of the AACR Special Conference: Advances in the Pathogenesis and Molecular Therapies of Liver Cancer; 2022 May 5-8; Boston, MA. Philadelphia (PA): AACR; Clin Cancer Res 2022;28(17_Suppl):Abstract nr PO012." @default.
• W4294163067 created "2022-09-02" @default.
• W4294163067 creator A5014942240 @default.
• W4294163067 creator A5015222907 @default.
• W4294163067 creator A5030350728 @default.
• W4294163067 creator A5040237243 @default.
• W4294163067 creator A5064003777 @default.
• W4294163067 creator A5067946262 @default.
• W4294163067 creator A5071265064 @default.
• W4294163067 date "2022-09-01" @default.
• W4294163067 modified "2023-10-16" @default.
• W4294163067 title "Abstract PO012: In silico drug repurposing identifies mebendazole as a treatment option for chemoresistant hepatoblastoma" @default.
• W4294163067 doi "https://doi.org/10.1158/1557-3265.liverca22-po012" @default.
• W4294163067 hasPublicationYear "2022" @default.
• W4294163067 type Work @default.
• W4294163067 citedByCount "0" @default.
• W4294163067 crossrefType "journal-article" @default.
• W4294163067 hasAuthorship W4294163067A5014942240 @default.
• W4294163067 hasAuthorship W4294163067A5015222907 @default.
• W4294163067 hasAuthorship W4294163067A5030350728 @default.
• W4294163067 hasAuthorship W4294163067A5040237243 @default.
• W4294163067 hasAuthorship W4294163067A5064003777 @default.
• W4294163067 hasAuthorship W4294163067A5067946262 @default.
• W4294163067 hasAuthorship W4294163067A5071265064 @default.
• W4294163067 hasConcept C126322002 @default.
• W4294163067 hasConcept C143998085 @default.
• W4294163067 hasConcept C18903297 @default.
• W4294163067 hasConcept C2776304256 @default.
• W4294163067 hasConcept C2776694085 @default.
• W4294163067 hasConcept C2778239845 @default.
• W4294163067 hasConcept C2779061029 @default.
• W4294163067 hasConcept C2781303535 @default.
• W4294163067 hasConcept C502942594 @default.
• W4294163067 hasConcept C71924100 @default.
• W4294163067 hasConcept C86803240 @default.
• W4294163067 hasConcept C98274493 @default.
• W4294163067 hasConceptScore W4294163067C126322002 @default.
• W4294163067 hasConceptScore W4294163067C143998085 @default.
• W4294163067 hasConceptScore W4294163067C18903297 @default.
• W4294163067 hasConceptScore W4294163067C2776304256 @default.
• W4294163067 hasConceptScore W4294163067C2776694085 @default.
• W4294163067 hasConceptScore W4294163067C2778239845 @default.
• W4294163067 hasConceptScore W4294163067C2779061029 @default.
• W4294163067 hasConceptScore W4294163067C2781303535 @default.
• W4294163067 hasConceptScore W4294163067C502942594 @default.
• W4294163067 hasConceptScore W4294163067C71924100 @default.
• W4294163067 hasConceptScore W4294163067C86803240 @default.
• W4294163067 hasConceptScore W4294163067C98274493 @default.
• W4294163067 hasIssue "17_Supplement" @default.
• W4294163067 hasLocation W42941630671 @default.
• W4294163067 hasOpenAccess W4294163067 @default.
• W4294163067 hasPrimaryLocation W42941630671 @default.
• W4294163067 hasRelatedWork W1993377100 @default.
• W4294163067 hasRelatedWork W1994797457 @default.
• W4294163067 hasRelatedWork W2048746306 @default.
• W4294163067 hasRelatedWork W2073683604 @default.
• W4294163067 hasRelatedWork W269281986 @default.
• W4294163067 hasRelatedWork W3031798271 @default.
• W4294163067 hasRelatedWork W363598932 @default.
• W4294163067 hasRelatedWork W4243635653 @default.
• W4294163067 hasRelatedWork W4246540349 @default.
• W4294163067 hasRelatedWork W4293776459 @default.
• W4294163067 hasVolume "28" @default.
• W4294163067 isParatext "false" @default.
• W4294163067 isRetracted "false" @default.
• W4294163067 workType "article" @default.